METASTATIC ENDOMETRIAL CANCER
Clinical trials for METASTATIC ENDOMETRIAL CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC ENDOMETRIAL CANCER trials appear
Sign up with your email to follow new studies for METASTATIC ENDOMETRIAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill takes aim at Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…
Matched conditions: METASTATIC ENDOMETRIAL CANCER
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 10:33 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called STC-15, either alone or combined with toripalimab, in people with advanced solid tumors or certain sarcomas (leiomyosarcoma and liposarcoma). The goal is to see if the treatment is safe and can shrink or control tumors. About 107 adults with can…
Matched conditions: METASTATIC ENDOMETRIAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: STORM Therapeutics LTD • Aim: Disease control
Last updated May 26, 2026 10:23 UTC
-
New hope for advanced cancers: first human trial of ERX-315 begins
Disease control Recruiting nowThis early-stage study tests a new drug called ERX-315 in people with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that no longer respond to standard treatments. The main goal is to check the drug's safety and find the best dose for future studies. About 15 …
Matched conditions: METASTATIC ENDOMETRIAL CANCER
Phase: PHASE1 • Sponsor: EtiraRx Australia Pty Ltd • Aim: Disease control
Last updated May 18, 2026 12:03 UTC